$PPCB

Propanc Biopharma (NASDAQ:PPCB) reported preclinical data for its pancreatic cancer treatment PRP, showing reduced cell proliferation, migration, and invasion in chemoresistant models. The study, conducted with Spanish universities, also showed upregulation of E-cadherin and EPCAM, and downregulation of Vimentin and Snail. PRP has FDA Orphan Drug Designation and a Phase 1b trial is planned for Q1 2027.

Propanc Biopharma (PPCB) announced a 1-for-10 reverse stock split to meet Nasdaq's $1.00 minimum bid price requirement. The split, effective October 26, 2026, will reduce outstanding shares from 10.33 million to 1.03 million. CEO James Nathanielsz stated it supports compliance efforts and development plans. PPCB is down 10.37% to $0.28.

Propanc Biopharma (Nasdaq: PPCB) reported preclinical research showing its pancreatic proenzyme formulation, PRP, reduced invasion of chemotherapy-resistant pancreatic cancer cells by 80% in lab tests. The study, led by Dr. Maria Belén Toledo, found PRP remodels resistant tumor states, increasing vulnerability to subsequent chemotherapy. Propanc plans to advance PRP to a Phase 1b clinical trial in Q1 2027.

Propanc Biopharma (NASDAQ:PPCB) published a peer-reviewed study in Scientific Reports on its pancreatic proenzyme combination PRP, showing anti-tumor efficacy in lab and animal models, and improved survival in human patients. The study evaluated PRP's impact on 24 cancer cell lines, with significant tumor weight reduction and no adverse events reported. The company is developing PRP for pancreatic, ovarian, and refractory prostate cancers.

Propanc Biopharma (PPCB) reported preclinical data for its PRP treatment in advanced pancreatic cancer, which has FDA Orphan Drug Designation. The company plans to begin a Phase 1b clinical trial in Q1 2027. PRP is still in early-stage development, and further regulatory approvals are required.

Propanc Biopharma (Nasdaq: PPCB) reported preclinical data showing its lead candidate PRP achieved over 90% tumor growth inhibition in pancreatic cancer models. PRP targets different mechanisms than Revolution Medicines' recently approved daraxonrasib, which showed median overall survival of 13.2 months in clinical trials. Propanc plans to start a Phase 1b study in early 2027.

Propanc Biopharma (PPCB) reported positive preclinical data for PRP in pancreatic cancer, showing over 90% tumor growth inhibition and extended survival in models. The treatment also improved chemo-resistance and tumor environment. PPCB stock surged 249.59% to $3.69 on Nasdaq. The company plans a Phase 1b study with a clinical trial application expected soon.

Propanc Biopharma, Inc. (PPCB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 INDEPENDENT DIRECTOR AGREEMENT THIS INDEPENDENT DIRECTOR AGREEMENT (this “ Agreement ”), is made effective as of July 8, 2026, and is by and between Propanc Biopharma, Inc., a Delaware corporation (the “ Company ”), and the undersigned (t

Propanc Biopharma (PPCB) said it signed an MOU with Avance Clinical Pty Ltd to collaborate on clinical delivery of its planned Phase 1b first-in-human trial of PRP for advanced solid tumors. The study will assess safety, tolerability, pharmacokinetics, immunogenicity, and preliminary activity. PPCB also noted a 1-for-25 reverse split on May 18, 2026.

Propanc Biopharma (Nasdaq: PPCB) said it signed an MOU with Avance Clinical Pty Ltd to support delivery of Propanc’s Phase 1b first-in-human trial of PRP in advanced solid tumors. The CRO will help with trial design and execution, aiming to generate data to move PRP toward proof-of-concept and later phases.